Clinical Trial: Isolated Limb Infusion of Chemotherapy in Treating Patients With Melanoma or Soft Tissue Sarcoma of the Arm or Leg That Cannot Be Removed By Surgery

This study is currently recruiting patients.

Sponsors and Collaborators: Memorial Sloan-Kettering Cancer Center
National Cancer Institute (NCI)
Information provided by: National Cancer Institute (NCI)

Purpose

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Infusing chemotherapy to the tumor area only may kill more tumor cells and cause less damage to healthy tissues.

PURPOSE: This phase II trial is studying isolated limb infusion of chemotherapy to see how well it works in treating patients with melanoma or soft tissue sarcoma of the arm or leg that cannot be removed by surgery.

Condition Treatment or Intervention Phase
stage III adult soft tissue sarcoma
recurrent adult soft tissue sarcoma
stage III melanoma
Stage IV Melanoma
Recurrent Melanoma
stage IV adult soft tissue sarcoma
 Drug: dactinomycin
 Drug: melphalan
 Procedure: chemotherapy
 Procedure: isolated limb infusion
Phase II

MedlinePlus related topics:  Melanoma;   Soft Tissue Sarcoma

Study Type: Interventional
Study Design: Treatment

Official Title: Phase II Study of Isolated Limb Infusion With Melphalan and Dactinomycin in Patients With Primary or Recurrent, Unresectable Regional Melanoma or Soft Tissue Sarcoma of the Extremity

Further Study Details: 

OBJECTIVES:

OUTLINE: Patients undergo fluoroscopic placement of angiographic arterial and venous catheters into the appropriate extremity. After the limb is warmed, melphalan and dactinomycin are rapidly infused into the isolated limb via the arterial catheter. Melphalan and dactinomycin are then recirculated for 20 minutes. Patients with little or no response at 8 weeks may receive up to 2 additional treatments at the discretion of the treating physician.

Patients are followed at 1-2 weeks, 3-4 weeks, 6-8 weeks, and then every 3-6 months thereafter as deemed necessary by the treating physician.

PROJECTED ACCRUAL: A total of 35 patients will be accrued for this study within 3 years.

Eligibility

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

DISEASE CHARACTERISTICS:

  • Histologically proven primary or recurrent, regional melanoma or soft tissue sarcoma that is not amenable to surgical resection
  • Majority (greater than 95%) of disease must be distal to the apex of the femoral triangle in the lower limb and the deltoid insertion in the upper limb
  • Bidimensionally measurable disease in the extremity
  • Patients with disease beyond the limb are eligible if their extremity disease requires palliative treatment in the judgment of their physician

PATIENT CHARACTERISTICS: Age:

  • Over 18

Performance status:

  • Karnofsky 70-100%

Life expectancy:

  • At least 6 months

Hematopoietic:

  • WBC at least 3,000/mm^3

Hepatic:

  • Not specified

Renal:

  • Creatinine less than 2.0 mg/dL

Cardiovascular:

  • Must have palpable femoral/axillary, dorsalis pedis/popliteal, or radial pulses in the extremity to be treated
  • No signs or symptoms of vascular insufficiency (no history of claudication or other ischemic peripheral vascular disease)

Other:

  • Not pregnant or nursing
  • Negative pregnancy test
  • No other concurrent serious illness
  • No severe diabetes
  • No prior extremity complications due to diabetes

PRIOR CONCURRENT THERAPY: Biologic therapy

  • Not specified

Chemotherapy

  • Not specified

Endocrine therapy

  • Not specified

Radiotherapy

  • Not specified

Surgery

  • Not specified

Other

  • At least 4 weeks since prior antitumor therapy and recovered
  • At least 2 weeks since prior antibiotics

Location and Contact Information


New York
      Memorial Sloan-Kettering Cancer Center, New York,  New York,  10021,  United States; Recruiting
Mary Susan Brady, MD  212-639-8347 

Study chairs or principal investigators

Mary Susan Brady, MD,  Study Chair,  Memorial Sloan-Kettering Cancer Center   

More Information

Clinical trial summary from the National Cancer Institute's PDQ® database

Study ID Numbers:  CDR0000067497; MSKCC-99047; NCI-G99-1664; NCT00004250
Record last reviewed:  October 2003
Last Updated:  February 24, 2005
Record first received:  January 28, 2000
ClinicalTrials.gov Identifier:  NCT00004250
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08


Source: ClinicalTrials.gov
Cache Date: April 9, 2005

Resources